Bellevue Life Sciences Acquisition Balance Sheet Health
Financial Health criteria checks 0/6
Bellevue Life Sciences Acquisition has a total shareholder equity of $-5.8M and total debt of $1.8M, which brings its debt-to-equity ratio to -30.9%. Its total assets and total liabilities are $20.9M and $26.7M respectively.
Key information
-30.9%
Debt to equity ratio
US$1.78m
Debt
| Interest coverage ratio | n/a |
| Cash | US$12.24k |
| Equity | -US$5.75m |
| Total liabilities | US$26.68m |
| Total assets | US$20.93m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BLAC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BLAC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BLAC has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BLAC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: BLAC's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if BLAC's interest payments on its debt are well covered by EBIT.